Signos bets FDA's OTC CGM category opens consumer weight loss; $20M Series B

Signos sells a metabolic health subscription: members wear a continuous glucose monitor (Dexcom Stelo OTC), log food and exercise in the app, and get real-time AI recommendations on how their body responds — aimed at weight management, not just diabetes care.

That FDA's new OTC CGM category lets consumers track glucose without a prescription — metabolic data as weight-loss product, with Signos' AI as the subscription layer.

$20M Series B (Oct 2023) led by Cheyenne Ventures and GV, joined by Dexcom Ventures and Samsung (TechCrunch).

Founded in 2019 in San Francisco by Sharam Fouladgar-Mercer, Signos started as a prescription-based metabolic platform pairing CGM data with an AI coaching engine. Fouladgar-Mercer, who struggled with weight since childhood, positioned CGM as a lifestyle tool for people without diabetes — TechCrunch cites more than 96 million Americans with prediabetes as the market.

In Oct 2023 Signos raised a $20M Series B from Cheyenne Ventures and GV, with Dexcom Ventures and Samsung on board (TechCrunch). When FDA cleared Dexcom Stelo as the first over-the-counter glucose biosensor in March 2024, Signos integrated it, removing the prescription barrier from its funnel. In Aug 2025 FDA cleared Signos' own OTC Glucose Monitoring System — the Stelo sensor plus Signos' AI — for weight management, the first such clearance, and Signos launched it to consumers and employers.

Still operating: selling the OTC program directly to consumers and through employers and health plans, positioned to work alongside GLP-1 programs; no exit announced.

The OTC clearance removed the prescription and doctor visit — the biggest friction in Signos' consumer funnel (Dexcom press release; HIT Consultant).

Signos had the software layer ready when the hardware category opened: AI engine, employer program and research built before the Stelo clearance (TechCrunch).

Strategic investors wired it into the category: Dexcom Ventures and Samsung joined the Series B alongside GV (TechCrunch).

The follow-on FDA clearance in Aug 2025 converted a partner-driven position into an owned regulatory position (HIT Consultant).

Ride someone else's regulatory breakthrough: Signos didn't build the sensor — it bet on Dexcom's OTC clearance, stacked its AI on top, then won its own clearance once the category existed.

As of 2026-09-02 Signos is still private and live: it sells the OTC Signos Glucose Monitoring System to consumers and rolls it out to employers and health plans, positioned to complement GLP-1 weight-loss programs. Its bet now depends on the OTC CGM category scaling beyond early adopters, and on consumers paying for the subscription layer; no revenue or membership figures are public.